Contact
+34 934 034 837
INVACO Acquires ENANTIA to Drive Expansion and Growth in Specialized CRO Services
Barcelona, January 29th, 2025
Enantia, a leading contract research organization (CRO) with over 20 years of experience in chemistry services, has been fully acquired by INVACO, a company controlled by the venture capital fund Inveready Biotech IV, which specializes in life sciences and health. This strategic acquisition marks the beginning of an ambitious growth plan, including the integration of specialized small CROs to provide comprehensive R&D services.
The transaction includes the participation of Enantia’s management team as shareholders, reinforcing their commitment to the company’s future. The collaboration between Enantia and Inveready will facilitate expansion into new markets while executing a targeted acquisition strategy to consolidate a group of highly specialized CROs serving the pharmaceutical, biotech, and materials industries.
Operating from its facilities at the Parc Científic de Barcelona and Esplugues de Llobregat, Enantia has built a strong reputation in medicinal chemistry, chemical process development, and solid-state R&D. With a team of highly skilled professionals, the company provides high-quality research and development services to an international client base.
Joan Feixas, CEO of Enantia, commented:
“We are grateful for Inveready’s trust in Enantia and our management team to lead the creation of a specialized R&D services group. This partnership comes at the right moment and under the right circumstances to drive significant growth. We are excited to be part of this project and look forward to expanding our impact in life sciences and beyond.”
Sara Secall, Partner at Inveready, stated:
“The preclinical CRO sector in Spain is highly fragmented. We created INVACO with the goal of acquiring specialized CROs in life sciences, and Enantia is the first step in building a stronger and more integrated group. This acquisition provides an exit for historical shareholders while ensuring the commitment of Enantia’s management team, who now hold a stake in INVACO. Our plan is to integrate additional CROs focused on preclinical drug development, including formulations, analytical and bioanalytical methods, toxicology, and pilot production.”
About Enantia
Founded in 2003 as a spin-off from the University of Barcelona, Enantia is a CRO specialized in chemical process R&D, solid-state R&D, and medicinal chemistry. The company has contributed to nearly 100 patent applications resulting from its research, collaborating annually with over 40 international pharmaceutical, biotech, and CDMO clients.
About Inveready
Inveready is a leading investment firm specializing in alternative assets, wealth management, and investment funds, managing over €1.9 billion. With a strong presence in the Spanish SME market, the firm has received multiple industry recognitions, including Best Venture Capital Firm (2017) by SpainCap and Best European Venture Debt Fund (2023) by Preqin. Inveready operates from its headquarters in San Sebastián, with additional offices in Barcelona and Madrid.
